BR112016022342B1 - Derivados de (5,6-di-hidro)pirimido[4,5-e] indolizinas, suas composições farmacêuticas, e seus usos - Google Patents

Derivados de (5,6-di-hidro)pirimido[4,5-e] indolizinas, suas composições farmacêuticas, e seus usos Download PDF

Info

Publication number
BR112016022342B1
BR112016022342B1 BR112016022342-0A BR112016022342A BR112016022342B1 BR 112016022342 B1 BR112016022342 B1 BR 112016022342B1 BR 112016022342 A BR112016022342 A BR 112016022342A BR 112016022342 B1 BR112016022342 B1 BR 112016022342B1
Authority
BR
Brazil
Prior art keywords
indolizine
carboxamide
dihydropyrimido
anilino
methoxy
Prior art date
Application number
BR112016022342-0A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112016022342A8 (pt
BR112016022342A2 (pt
Inventor
Adrianus Petrus Antonius De Man
Rogier Christian Buijsman
Jan Gerard Sterrenburg
Joost Cornelis Marinus Uitdehaag
Joeri Johannes Petrus De Wit
Guido Jenny Rudolf Zaman
Original Assignee
Netherlands Translational Research Center B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Netherlands Translational Research Center B.V. filed Critical Netherlands Translational Research Center B.V.
Publication of BR112016022342A2 publication Critical patent/BR112016022342A2/pt
Publication of BR112016022342A8 publication Critical patent/BR112016022342A8/pt
Publication of BR112016022342B1 publication Critical patent/BR112016022342B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112016022342-0A 2014-04-07 2015-03-30 Derivados de (5,6-di-hidro)pirimido[4,5-e] indolizinas, suas composições farmacêuticas, e seus usos BR112016022342B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14163734 2014-04-07
EP14163734.8 2014-04-07
EP15153207 2015-01-30
EP15153207.4 2015-01-30
PCT/EP2015/056839 WO2015155042A1 (en) 2014-04-07 2015-03-30 (5,6-dihydro)pyrimido[4,5-e]indolizines

Publications (3)

Publication Number Publication Date
BR112016022342A2 BR112016022342A2 (pt) 2017-08-15
BR112016022342A8 BR112016022342A8 (pt) 2021-07-20
BR112016022342B1 true BR112016022342B1 (pt) 2022-10-04

Family

ID=52774240

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016022342-0A BR112016022342B1 (pt) 2014-04-07 2015-03-30 Derivados de (5,6-di-hidro)pirimido[4,5-e] indolizinas, suas composições farmacêuticas, e seus usos

Country Status (16)

Country Link
US (3) US9856258B2 (enExample)
EP (1) EP3129374B1 (enExample)
JP (1) JP6518690B2 (enExample)
KR (1) KR102432420B1 (enExample)
CN (1) CN106132963B (enExample)
AU (1) AU2015243694B2 (enExample)
BR (1) BR112016022342B1 (enExample)
CA (1) CA2944610C (enExample)
DK (1) DK3129374T3 (enExample)
ES (1) ES2716165T3 (enExample)
HU (1) HUE043108T2 (enExample)
MX (1) MX368767B (enExample)
PL (1) PL3129374T3 (enExample)
PT (1) PT3129374T (enExample)
RU (1) RU2692479C2 (enExample)
WO (1) WO2015155042A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015155042A1 (en) * 2014-04-07 2015-10-15 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido[4,5-e]indolizines
US11208696B2 (en) 2015-04-17 2021-12-28 Netherlands Translational Research Center B.V. Prognostic biomarkers for TTK inhibitor chemotherapy
ES2858753T3 (es) * 2016-02-19 2021-09-30 Phoenix Molecular Designs Derivados de 6-oxo-N-(1-(bencil)-1H-pirazol-4-il)-6,7,8,9-tetrahidropirido[3',2':4,5]pirrolo[1,2-a]pirazin-2-carboxamida como inhibidores de cinasa S6 ribosómica (RSK) p90 para el tratamiento del cáncer
CN109311848B (zh) 2016-06-07 2022-02-01 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
CN106551938B (zh) * 2016-11-26 2017-11-24 广东安诺药业股份有限公司 一种治疗非酒精性脂肪肝的药物及其应用
SMT202400385T1 (it) 2017-03-23 2024-11-15 Jacobio Pharmaceuticals Co Ltd Nuovi derivati eterociclici utili come inibitori di shp2
US20210393623A1 (en) 2018-09-26 2021-12-23 Jacobio Pharmaceuticals Co., Ltd. Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
EP3924352A4 (en) 2019-02-11 2022-11-16 Phoenix Molecular Designs CRYSTALLINE FORMS OF AN RSK INHIBITOR
KR20240107189A (ko) * 2021-12-15 2024-07-08 신라젠(주) 신생물성 질환 치료에 사용하기 위한 약제학적 병용물
AU2022408915A1 (en) * 2021-12-15 2024-06-27 Sillajen, Inc. Methods of treating neoplastic diseases
US20250049926A1 (en) * 2021-12-15 2025-02-13 Sillajen, Inc. Pharmaceutical compositions comprising modified betacyclodextrins
AU2023228543A1 (en) * 2022-03-04 2024-08-22 Sillajen, Inc. Pharmaceutical combinations for use in the treatment of neoplastic diseases.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002337142B2 (en) * 2001-09-19 2007-10-11 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
US7482354B2 (en) 2003-05-22 2009-01-27 Nerviano Medical Sciences S.R.L. Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
EP2118102B1 (en) 2006-11-28 2013-06-12 Nerviano Medical Sciences S.r.l. Tricyclic indoles and (4,5-dihydro) indoles
HRP20160243T1 (hr) * 2008-06-26 2016-04-08 Les Laboratoires Servier Pirazolo-kinazolini kao modulatori aktivnosti protein kinaze
WO2010111406A2 (en) 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
CN102428086B (zh) 2009-04-29 2014-08-20 内尔维阿诺医学科学有限公司 Cdk抑制剂的盐类
CN103626777B (zh) 2009-07-29 2015-10-21 内尔维阿诺医学科学有限公司 Plk抑制剂的盐类
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
US20130303532A1 (en) * 2010-12-17 2013-11-14 Bayer Intellectual Property Gmbh Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders
BR112013018515B1 (pt) * 2011-01-26 2021-06-29 Nerviano Medical Sciences S.R.I Derivados de pirrol tricíclico, processo para sua preparação e seu uso como inibidores da quinase
JP6523267B2 (ja) 2013-06-24 2019-05-29 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Fshrの調節剤としてのイミダゾール化合物及びその使用
WO2015155042A1 (en) * 2014-04-07 2015-10-15 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido[4,5-e]indolizines

Also Published As

Publication number Publication date
KR20170013866A (ko) 2017-02-07
RU2016141405A3 (enExample) 2018-10-02
BR112016022342A8 (pt) 2021-07-20
PT3129374T (pt) 2019-03-25
BR112016022342A2 (pt) 2017-08-15
EP3129374A1 (en) 2017-02-15
MX2016012997A (es) 2016-12-07
RU2692479C2 (ru) 2019-06-25
JP2017510595A (ja) 2017-04-13
DK3129374T3 (en) 2019-04-08
US20170096432A1 (en) 2017-04-06
WO2015155042A1 (en) 2015-10-15
ES2716165T3 (es) 2019-06-10
JP6518690B2 (ja) 2019-05-22
USRE50082E1 (en) 2024-08-20
CA2944610A1 (en) 2015-10-15
HUE043108T2 (hu) 2019-07-29
AU2015243694B2 (en) 2019-01-17
CN106132963B (zh) 2019-08-06
AU2015243694A1 (en) 2016-11-03
USRE48974E1 (en) 2022-03-15
CN106132963A (zh) 2016-11-16
RU2016141405A (ru) 2018-05-07
CA2944610C (en) 2024-01-09
EP3129374B1 (en) 2018-12-19
KR102432420B1 (ko) 2022-08-17
MX368767B (es) 2019-10-15
PL3129374T3 (pl) 2019-07-31
US9856258B2 (en) 2018-01-02

Similar Documents

Publication Publication Date Title
US9856258B2 (en) (5,6-dihydro)pyrimido[4,5-E]indolizines
JP7553450B2 (ja) ユビキチン特異的プロテアーゼ1を阻害するための組成物
JP6726677B2 (ja) 抗がん剤としての置換2−h−ピラゾール誘導体
KR102472198B1 (ko) Pi3k 베타 저해제로서의 아자벤즈이미다졸 유도체
TW202309027A (zh) 作為parp抑制劑的化合物
RS61701B1 (sr) Jedinjenja amino-triazolopiridina i njihova upotreba u lečenju kancera
AU2014225155B2 (en) Pyridopyrimidine or pyrimidopyrimidine compound, preparation method, pharmaceutical composition and use thereof
KR20210144853A (ko) 암 치료를 위한 n-헤테로방향족 아미드 유도체
AU2021289169B2 (en) Spiro compounds as melanocortin 4 receptor antagonists and uses thereof
AU2013344049A1 (en) ALK kinase inhibitors
KR101739003B1 (ko) 신규한 트리아졸로피리미디논 또는 트리아졸로피리디논 유도체, 및 이들의 용도
JP2024521879A (ja) 置換フェニル-1H-ピロロ[2,3-c]ピリジン誘導体
Liu et al. Pyridazinone derivatives displaying highly potent and selective inhibitory activities against c-Met tyrosine kinase
US20230348462A1 (en) Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
JP6586463B2 (ja) PI3Kβ阻害剤としての複素環連結イミダゾピリダジン誘導体
WO2025099307A1 (en) Compounds and pharmaceutical compositions thereof for the treatment of diseases
IL322876A (en) A disintegrant containing an aryl substituent for CDK12/13, a method for its preparation, as well as a pharmaceutical composition and medical use thereof
CA3225596A1 (en) Inhibitors targeting ubiquitin specific protease 7 (usp7)
CN116529251A (zh) 取代的稠合双环化合物作为激酶抑制剂及其应用
CN103570731A (zh) 嘧啶并三环或嘧啶并四环类化合物及其药用组合物和应用
BR112019020309A2 (pt) derivados de quinoxalina e piridopirazina como inibidores de pi3k-beta
HK1231072A1 (en) (5,6-dihydro)pyrimido[4,5-e]indolizines
HK1231072B (zh) (5,6-二氢)嘧啶并[4,5-e]吲嗪
KR20250121126A (ko) Irak3의 리간드 지정 분해제로서의 치환된 이미다조-기재 화합물
WO2022070071A1 (en) Dihydroorotate dehydrogenase inhibitors

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/03/2015, OBSERVADAS AS CONDICOES LEGAIS